Southeastern Retina Associates PC

01/29/2026

AAVantgarde is developing new gene therapies for Stargardt disease and retinitis pigmentosa. With support from AGC Biologics and $141 million in funding, they’re now testing these treatments in early clinical trials using a new dual-vector approach that may help more patients. Learn more: https://www.ophthalmologytimes.com/view/agc-biologics-to-manufacture-aavantgarde-s-dual-vector-gene-therapies-for-inherited-retinal-disorders-aavb-039-and-aavb-081

Both therapeutics will leverage AGC Biologics’ BravoAAV suspension platform and use an innovative dual AAV vector approach, which splits the therapeutic gene into 2 halves.

01/27/2026

Meet Dr. Claxton Baer, a board-certified retina specialist who is seeing patients in Johnson City, Kingsport, Bristol, and Abingdon. With advanced training from Duke and Emory, he brings expertise in retinal surgery to serve Eastern Tennessee and Southwest Virginia. Learn more: https://www.southeasternretina.com/retina-specialists/dr-claxton-a-baer

01/22/2026

Looking for expert retina care close to home? Our Athens, TN location offers advanced treatment for retinal conditions, serving patients from Madisonville, Sweetwater, Decatur, and surrounding areas. Learn more: https://www.southeasternretina.com/retina-centers/athens

01/20/2026

Kiora Pharmaceuticals has received a new U.S. patent for its non-steroidal eye drug KIO-104, designed to treat retinal inflammation without the side effects of steroids. The medication is currently being studied in a Phase 2 trial for conditions like uveitis and diabetic macular edema, aiming to help preserve vision for patients with inflammatory eye diseases. Learn more: https://www.ophthalmologytimes.com/view/kiora-pharmaceuticals-receives-patent-for-additional-and-novel-formulations-of-kio-100-compounds

Kiora Pharmaceuticals advances ocular therapies with new patents for KIO-104, targeting retinal inflammation and enhancing treatment options.

01/15/2026

Grateful for kind words like this from our patients. From advanced treatments like PDT to everyday care, our team is here to make every visit as smooth and comfortable as possible.

01/13/2026

Belite Bio’s phase 3 trial showed that Tinlarebant significantly slowed retinal damage in teens with Stargardt disease. This is the first treatment to show meaningful results for this rare inherited eye condition, offering new hope to patients. Learn more: https://www.ophthalmologytimes.com/view/belite-bio-releases-topline-results-from-phase-3-dragon-trial-of-tinlarebant-for-stgd1

The DRAGON trial was a 24-month pivotal phase 3 trial evaluating Tinlarebant in adolescent STGD1 patients.

01/08/2026

New data shows that aflibercept 8 mg (EYLEA HD) is a safe and effective long-term treatment for patients with retinal conditions. Patients are seeing better results with fewer injections, helping reduce treatment burden and clinic visits. Learn more: https://www.ophthalmologytimes.com/view/8-things-to-know-aflibercept-8-mg-retinal-vascular-disease

A trio of retina specialists recently reviewed the clinical benefits of aflibercept 8 mg, including its extended dosing intervals, improved patient satisfaction, and enhanced treatment outcomes for various conditions.

01/06/2026

Meet Dr. Nicholas G. Anderson, a Knoxville native and board-certified retina specialist. Known for both his clinical excellence and compassionate care, he’s been consistently recognized by peers and patients alike for his dedication to retinal health. Learn more: https://www.southeasternretina.com/retina-specialists/dr-nicholas-g-anderson

01/01/2026

Happy New Year from all of us at Southeastern Retina Associates! We’re grateful for the trust you placed in us this past year and look forward to continuing to care for your vision in 2026. Wishing you a healthy year ahead!

12/29/2025

Visiting Southeastern Retina Associates for the first time? Your appointment will include a comprehensive eye exam with pupil dilation and may last up to three hours. Be sure to bring your ID, insurance cards, medication list, sunglasses, and someone to drive you home. New patient forms are available online to complete ahead of time. Learn more: https://www.southeasternretina.com/resources

At SERA, our physicians and staff are committed to providing individualized attention and the best care possible. Learn more about your first visit.

12/23/2025

Nanoscope Therapeutics reported strong long-term results for their treatment MCO-010, designed for people with advanced retinitis pigmentosa. Just one injection was shown to be safe over five years, with some patients experiencing better vision and improved quality of life. This treatment could offer new hope for those with severe vision loss. Learn more: https://www.ophthalmologytimes.com/view/nanoscope-therapeutics-releases-positive-long-term-safety-results-from-extend-study

The EXTEND study is a 5-year follow-up of participants who received a single intravitreal injection of MCO-010 in a previously conducted phase 1/2a trial.

12/22/2025

Curious about clinical trials? At Southeastern Retina Associates, our team leads and participates in research that helps shape the future of retinal care. By joining a trial, you help us bring better treatments to patients who need them most.